Compare Amphastar Pharmaceuticals Inc (AMPH) vs Zoom Video Communications, Inc. (ZM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Zoom Video Communications, Inc. — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Zoom Video Communications, Inc. trades at $106 (market cap $31.43B). The key difference: Zoom Video Communications, Inc. is far larger — about 36.4× Amphastar Pharmaceuticals Inc's market cap, and Zoom Video Communications, Inc. is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | ZM | |
|---|---|---|
Market Cap | $863.95M | $31.43B |
Sector | Health | Technology |
52-Week High | $30.81 | $111.88 |
52-Week Low | $16.87 | $69.96 |
Enterprise Value | $1.26B | $23.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Zoom Communications (ZM) trades at $104.50, up 3.16% on the day, with a bullish technical signal and strong moving average support. The stock shows robust profitability with a 77.4% gross margin and 42% net income margin, while recent earnings beat expectations in Q1 2026. Analyst consensus price target is $118.79, suggesting potential upside from current levels. Recent news highlights insider selling and AI product developments, including Zoom Virtual Agent Receptionist launches and APAC leadership appointments.
Outlook remains cautiously optimistic with solid fundamentals and technical momentum, but risks include insider selling pressure and competitive threats. The stock's valuation at 15.4x P/E appears reasonable given earnings growth, though investors should monitor Q2 2026 earnings due August 25, 2026, for confirmation of sustained performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Zoom Video Communications, Inc.
Zoom Video Communications, Inc. develops a people-centric cloud service that transforms real-time collaboration experience. The Company offers unified meeting experience, a cloud service that provides a 3-in-1 meeting platform with HD video conferencing, mobility, and web meetings. Zoom Video Communications serves customers worldwide.
Read more on ZM →
